A new report from the Nordic Expert Group (NEG) and the Dutch Expert DECOS committee has evaluated the health hazards and calculated cancer risk of occupational exposure to respirable crystalline silica (RCS). Several experts ...
Sep 10, 2024
0
0
The ROS1 tyrosine kinase inhibitor (TKI) taletrectinib demonstrated high overall and intracranial responses, and a favorable safety profile with low incidence of neurologic adverse events in TKI-naive and TKI-pretreated patients ...
Sep 10, 2024
0
0
The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing, epidermal growth factor receptor ...
Sep 10, 2024
0
0
Recent air pollution exposure in the form of particles smaller than 2.5 micrometers (PM2.5) exposure may significantly impact lung cancer in women who have never smoked, with notable differences in stage IV diagnoses among ...
Sep 10, 2024
0
0
A Phase III study comparing tusamitamab ravtansine with docetaxel in patients with advanced non-squamous non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and immunotherapy (in combination ...
Sep 10, 2024
0
0
Treatment with BAY 2927088 led to rapid, substantial, and durable responses in patients with heavily pretreated HER2-mutant non-small cell lung cancer (NSCLC), according to research presented at the International Association ...
Sep 9, 2024
0
0
The HER2-specific tyrosine kinase inhibitor zongertinib was well tolerated and demonstrated promising efficacy in patients with HER2 mutation-positive non-small cell lung cancer, meeting the primary endpoint of the Beamion ...
Sep 9, 2024
0
0
The combination of osimertinib and savolitinib showed clinically meaningful improvement in objective response rate compared to osimertinib alone, according to research presented at the International Association for the Study ...
Sep 9, 2024
0
0
Phase 2 results from the NeoCOAST-2 study have demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete response rates among the tested regimens.
Sep 8, 2024
0
0
Data from a Phase 3 study has revealed that ivonescimab demonstrates a statistically significant and clinically meaningful improvement in progression-free survival compared to pembrolizumab for patients with PD-L1-positive ...
Sep 8, 2024
0
0
